Keiji Nishibeppu

Dr. Keiji Nishibeppu

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
KNKeiji Nishibeppu
Keiji Nishibeppu
SKShuhei Komatsu
Shuhei Komatsu
DIDaisuke Ichikawa
Daisuke Ichikawa
TITaisuke Imamura
Taisuke Imamura
TKToshiyuki Kosuga
Toshiyuki Kosuga
EOEigo Otsuji
Eigo Otsuji
Although adjuvant chemotherapy with S-1 after curative gastrectomy has been performed as a standard treatment for Stage II and III gastric cancer (GC) in Japan, patients with Stage III GC still have a high incidence of recurrence and a poor prognostic outcome. The aim of this study was to investigate risk factors for recurrence in patients with Stage III GC despite of curative gastrectomy followed by adjuvant chemotherapy, suggesting an indicator for more intensive management. A total of 97 patients with pathological Stage III GC underwent adjuvant chemotherapy after curative gastrectomy between 2001 and 2014, were enrolled in this study. We retrospectively analyzed their hospital records from our hospital. The 5-year relapse-free survival (RFS) rates of patients with pStage III GC were 42.0%. Univariate and multivariate analyses for RFS revealed that venous invasion (v+) was an independent factor predicting a shorter RFS (v + vs. v-, 36.5% vs. 47.4%, P = 0.034, HR 1.82, 95% CI: 1.01–3.37). Venous invasion also predicted a shorter overall survival (OS) (v + vs. v-, 33.7% vs. 50.4%, P = 0.027). Regarding the patterns of recurrence, hematogenous recurrence was significantly occurred in patients with v + GC than those without (P = 0.022). Stage III GC with venous invasion is a high-risk subgroup for hematogenous recurrence after curative surgery followed by adjuvant chemotherapy. More intensive and effective adjuvant chemo and/or molecular targeted therapy for Stage III GC patients with venous invasion should be considered to improve their outcomes.

4 January 2019 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
JKJun Kiuchi
Jun Kiuchi
SKShuhei Komatsu
Shuhei Komatsu
TITaisuke Imamura
Taisuke Imamura
KNKeiji Nishibeppu
Keiji Nishibeppu
KSKatsutoshi Shoda
Katsutoshi Shoda
EOEigo Otsuji
Eigo Otsuji
Recent studies identified that low levels of tumour suppressor microRNAs (miRNAs) in plasma/serum relate to tumour progression and poor outcomes in cancers. We selected six candidates (miR-126, 133b, 143, 203, 338-3p, 655) of tumour suppressor miRNAs in oesophageal squamous cell carcinoma (ESCC) by a systematic review of NCBI database. Of these, miR-655 levels were significantly down-regulated in plasma of ESCC patients compared to healthy volunteers by test- and validation-scale analyses. Low levels of plasma miR-655 were significantly associated with lymphatic invasion, lymph node metastasis and advanced stage. Univariate and multivariate analysis revealed that the low level of plasma miR-655 was an independent risk factor of lymphatic progression and a poor prognostic factor. Overexpression of miR-655 in ESCC cells inhibited cell proliferation, migration, invasion and epithelial-mesenchymal transition. Increased plasma miR-655 levels by the subcutaneous injection significantly inhibited lymph node metastasis in mice. Low levels of miR-655 in plasma relate to lymphatic progression and poor outcomes, and the restoration of the plasma miR-655 levels might inhibit tumour and lymphatic progression in ESCC.

6 September 2022 in Langenbeck's Archives of Surgery
Verified
Journal Article
Closed access
PDF file
KNKeiji Nishibeppu
Keiji Nishibeppu
SSShinichi Sakuramoto
Shinichi Sakuramoto
KMKazuaki Matsui
Kazuaki Matsui
GEGen Ebara
Gen Ebara
SFShohei Fujita
Shohei Fujita
KYKeishi Yamashita
Keishi Yamashita

15 May 2023 in Cancer Science
Verified
Journal Article
Open access
YTYusuke Takashima
Yusuke Takashima
SKShuhei Komatsu
Shuhei Komatsu
TOTakuma Ohashi
Takuma Ohashi
JKJun Kiuchi
Jun Kiuchi
KNKeiji Nishibeppu
Keiji Nishibeppu
EOEigo Otsuji
Eigo Otsuji
This study investigated novel tumor suppressor microRNAs (miRNAs) that decrease in plasma and predict chemosensitivity to neoadjuvant chemotherapy (NAC) for esophageal squamous cell carcinoma (ESCC) and revealed their usefulness as novel therapeutic agents. We selected four miRNA candidates (miR-323, 345, 409, and 1254) based on the microRNA microarray comparing pre-treatment plasma levels in ESCC patients with high and low histopathological responses to NAC and an NCBI database review. Among these miRNA candidates, miR-1254 was more highly elevated in pre-treatment plasma of ESCC patients with a high histopathological response than in those with a low histopathological response (P = 0.0021, area under the receiver-operating characteristic curve 0.7621). High plasma miR-1254 levels tended to correlate with the absence of venous invasion (P = 0.0710) and were an independent factor predicting a higher response to chemotherapy (P = 0.0022, odds ratio 7.86) and better prognosis (P = 0.0235, hazard ratio 0.23). Overexpressing miR-1254 in ESCC cells significantly enhanced chemosensitivity to cisplatin through the transcriptional regulation of ABCC1 in vitro. Moreover, increased plasma miR-1254 levels by subcutaneous injection significantly improved responses to cisplatin in mice. Plasma miR-1254 might be a useful biomarker for predicting responses to NAC, and the restoration of plasma miR-1254 levels might improve chemosensitivity in ESCC.

1 January 2026 in Journal of Gastric Cancer
Verified
Journal Article
Open access
PDF file
TOTakuma Ohashi
Takuma Ohashi
TKTakeshi Kubota
Takeshi Kubota
HFHayato Fukui
Hayato Fukui
ODOsamu Dohi
Osamu Dohi
SKShuhei Komatsu
Shuhei Komatsu
ASAtsushi Shiozaki
Atsushi Shiozaki
Ohashi T, et al. J Gastric Cancer. 2026 Apr;26(2):232-246. https://doi.org/10.5230/jgc.2026.26.e15

20 January 2022 in Surgery Today
Verified
Journal Article
Closed access
PDF file
KMKazuaki Matsui
Kazuaki Matsui
SSShinichi Sakuramoto
Shinichi Sakuramoto
HSHirofumi Sugita
Hirofumi Sugita
KNKeiji Nishibeppu
Keiji Nishibeppu
GEGen Ebara
Gen Ebara
Keishi YamashitaKeishi Yamashita
Keishi Yamashita